Updated October 25, 2026 · Sources linked below
“It is not working” can describe several different experiences: little initial weight change, a plateau after substantial loss, return of appetite, or side effects that make treatment difficult to continue. Those situations call for different conversations.
Before deciding that a treatment has failed, define what you expected and what has actually happened. Bring the timeline rather than only the latest scale reading.
Separate early response from later maintenance
The first weeks of a prescribed treatment may involve gradual adjustment and assessment of tolerability. Expectations should follow the specific product and treatment plan. A clinician should explain when response will be evaluated and what would justify changing course. Do not increase a dose or shorten an interval on your own.
A plateau after weight reduction is different from little response from the outset. Ongoing treatment may help maintain a lower weight even when the scale is no longer falling. Randomized withdrawal evidence with tirzepatide shows that stopping treatment can lead to weight regain. [1]
Review barriers without assigning blame
Discuss missed doses, medication access, storage concerns, side effects, and changes in other medicines. Review eating adequacy, activity, sleep, and relevant medical conditions. These are parts of understanding treatment response, not an accusation that a patient has failed to try hard enough.
NIDDK advises evaluating a weight-management medicine in the context of benefits, adverse effects, health conditions, other medicines, and cost. The appropriate decision can include continuing, changing, or stopping treatment under supervision. [2]
Bring a useful record
Write down treatment start dates, prescribed changes, missed doses, side effects, and the timing of weight measurements. Include other outcomes that matter, such as mobility or relevant laboratory trends. A consistent record is more informative than weighing repeatedly throughout a day.
Ask for a clear next review date and the criteria that will guide the decision. If cost or supply is the barrier, raise it early so the clinician can help plan a safe transition or interruption.
Does returning hunger prove the medicine no longer works?
No. Appetite is one experience among several; it does not by itself establish loss of all treatment benefit.
Should I add a “fat-loss peptide” to restart progress?
Do not add an unapproved compound or combine treatments on your own. Each proposed product and combination needs its own evidence and safety assessment; a plateau does not supply that evidence.
Sources and further reading
- Aronne et al. SURMOUNT-4 randomized withdrawal trial. JAMA, 2024
- NIDDK: prescription medications to treat overweight and obesity
Patient education from OlympusMD Wellness in Milton, Georgia. This article provides general information and does not replace an individual medical evaluation.
